With the implementation of the EU HTA (Regulation (EU) 2025/117) and ongoing adaptation of methods u...
Read moreAs the regulatory and market access landscape continues to evolve across Europe, timely and strategi...
Read moreIn the current pharmaceutical environment, obtaining regulatory approval is no longer enough to ensu...
Read moreThe long-anticipated EU Health Technology Assessment (HTA) Regulation (Regulation (EU) 2021/2282) wa...
Read moreThe advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p...
Read moreThe population, intervention, comparator, and outcomes (PICO) element of the upcoming EU Joint Clini...
Read moreAUTHORS: Julia Tokarska, Ella Odams, Richard Sloggett, Graham Foxon OBJECTIVES To evaluate if ...
Read moreEU HTA Regulation goes live: A new era for HTA begins The much-awaited implementation of the r...
Read moreThe National Healthcare Security Administration (NHSA) of China completed its annual review of the N...
Read moreWe examine how real-world evidence strategies help address uncertainties in rare disease treatments ...
Read more